1	
2	
3	
4	Safety and efficacy of orally administered full-spectrum medicinal cannabis plant
5	extract 0.08% THC (NTI-164) in children with autism spectrum disorder:
6	An open-label study
7	
8	
9	Dima El-Sukkari ¹ , Kanan Sharma ¹ , Bobbi Fleiss ² , Dion L. Braganza ¹ , Alison Crichton ^{3,4,}
10	Michael C. Fahey 1*
11	
12	¹ Monash Children's Hospital, Clayton, Victoria, Australia
13	^{2.} RMIT University, STEM College, Bundoora, Victoria, Australia
14	³ Department of Paediatrics, Monash University,
15	⁴ Developmental Paediatrics, Department of Paediatrics, Monash Children's Hospital
16	
17	*Corresponding author
18	E-mail: Michael.Fahey@monash.edu
19	
20	
21	Funding This study was supported by Fenix Innovations.
22	
23	
24	

Abstract

Autism spectrum disorder (ASD) is commonly associated with debilitating comorbidities impacting the well-being of affected children and their families. Some children with ASD experience behavioural difficulties that do not respond well to current medications and may also experience unwanted side effects. Therefore, it is crucial to develop alternative, safe and effective therapies. The improved understanding of the endocannabinoid system, together with emerging evidence for the therapeutic effects of cannabis derivatives in neurodevelopment disorders, has led to an exploration of their use in ASD.

This open-label study assessed the efficacy and safety of a novel oil-based full-spectrum medicinal cannabis plant extract 0.08% THC (NTI-164) in treating 14 children with ASD symptoms (13.4 years, range 10-17). Data on the safety profile of NTI-164 was collected through biochemical analysis, vital signs, and parent and participant reports. The efficacy was assessed through a dose-escalation protocol using a broad range of validated clinical behavioural assessments and parent and child-reported questionnaires.

Following four weeks of treatment with NTI-164, 93% of participants demonstrated significant overall improvement in ASD-related symptoms compared to baseline with transient side effects that did not interfere with their general functioning. In addition, targeted behavioural problems were rated as much improved or very much improved in 46% of the treated patients. More than half of caregivers and children also reported decreased anxiety symptoms.

The findings from this study suggest that NTI-164 is well-tolerated and safe, with potential clinical benefits in improving disruptive behaviours and reducing anxiety in children with ASD-related symptoms. Future longitudinal and well-controlled studies are warranted to develop evidence-based clinical therapies and further evaluate the therapeutic benefit of full-

spectrum cannabis extracts in managing ASD core and associated comorbid symptoms in this group of children.

Trial registration number ACTRN12621000760875

Introduction

Autism Spectrum Disorder (ASD) is a group of pervasive neurodevelopmental disorders that appear in early childhood. These disorders are characterised by social functioning deficits, restricted or repeated patterns of behaviour across the lifespan [1], and other comorbidities such as intellectual disabilities, epilepsy, anxiety, hyperactivity, irritability, and sleep disturbances. [2, 3] These symptoms can significantly impact a person's daily functioning. [4, 5] Globally, the prevalence of ASD is estimated to range from 0.4% to 1.7% [6]. In the last decade, the prevalence rate of young children (under five years) diagnosed with ASD has increased by 6.7%, from 2.7 million in 1990 to 2.9 million in 2019 [7].

The families of children with ASD face a substantial financial burden, with recent global estimates indicating 2834 EUR total costs for health-related services combined with indirect societal costs over two months [8]. The estimated lifetime social cost in the US alone was \$7 trillion for the last three decades (1990-2019) and is forecasted to increase to \$11-15 trillion in the following decade [9]. The continuing rise in ASD prevalence is further projected to generate an enormous economic burden on US healthcare for decades and to reach an annual cost estimate of \$5.54 trillion by 2060, with substantial potential yearly savings of \$1.9 trillion through ASD prevention strategies [10]. Despite thorough investigation, no evidence supports the effectiveness of pharmacological treatments in relieving some of the symptoms that cause people with ASD distress. [11, 12]. However, these pharmacological treatments often result in

adverse side effects in children, with a notable variation in effectiveness between individuals [13] and a lack of adherence [14]. The complexity of the ASD behavioural phenotype and its aetiology resulting from the interaction of multiple genetic and environmental risk factors further limits targeted interventions and the development of effective therapies [15, 16]. Therefore, to address core behaviours and co-morbid symptoms associated with ASD, targeted therapeutic interventions are urgently needed.

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

The endocannabinoid system (ECS), consisting of cannabinoid receptors (CB1 and CB2), endocannabinoids (endogenous bioactive ligands) and metabolic enzymes [17] presents as a potential pharmacological target for developing therapeutics in the management of ASD symptoms since it has a crucial role in modulation of neuronal plasticity during development [18] and associated with social-emotional processes [19] which are impaired in ASD-related phenotypes [20, 21]. The central endocannabinoid receptors CB1 and CB2 are expressed mainly in sensory neurons and immune cells, including microglia [17]. The endogenous cannabinoids are produced as required, activating presynaptic receptors to reduce calcium uptake and inhibit the release of neurotransmitters, consequently influencing a broad range of biological responses [22]. Alterations in ECS functionality have been reported in several preclinical ASD models [23-25] and clinical studies [26-28], suggesting that ASD pathogenesis likely involves dysregulation of the endocannabinoid signalling pathway. These findings suggest that endocannabinoid anandamide (AEA) and its associated metabolic enzymes may be a potential therapeutic target for ASD-related behavioural impairment. In animal studies, treatment with inhibitors of the enzyme fatty acid amide hydrolase that degrades anandamide resulted in increased AEA levels, restoring cognitive and social deficits in the ASD-related knockout models [29-31].

The increased understanding of the ECS signalling concurrent with growing evidence for the therapeutic effects of cannabis (*Cannabis sativa* L.) in neurodevelopment disorders has

been the catalyst for extensive research on the two most abundant active constituents Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD). During the last two decades, there has been a surge in clinical trials of CBD owing to the absence of psychoactive effects and its confirmed favourable safety profile in humans for the treatment of several neurological and psychiatric disorders [32-34]. In addition, accumulating evidence from experimental and animal model studies on the effect of CBD has demonstrated modulation of a broad range of biological responses, including antidepressant [35], anti-inflammatory [36], antinociceptive [37], anti-seizure [38], immunomodulatory [39] and neuroprotective activities [40]. Cannabinoids are generally well-tolerated, but evidence suggests that the risk of hepatotoxicity may be increased when combined with other medications. This risk is usually low, dose-dependent, and more likely to occur in individuals with a history of liver disease.[41] Rigorous controlled clinical studies are needed to determine the efficacy and safety profile of cannabinoids in children.

There is growing evidence that using CBD in combination with other plant compounds found in cannabis as a full-spectrum botanical medicine could provide unique therapeutic benefits, as suggested by anecdotal reports and emerging research in the field. [42] This effect, known as the entourage effect, was initially proposed as a regulatory mechanism for the endocannabinoid system, whereby multiple compounds enhance the activity of endogenous cannabinoids. A recent meta-analysis of observational studies showed that twice as many patients with treatment-resistant epilepsy improved when treated with an herbal formulation that offered a better safety profile than isolated CBD product [46]. Furthermore, promising evidence from preclinical cancer models supports the potential for the entourage effect of botanical preparations to produce enhanced therapeutic responses than individual cannabinoids [47-49]. Given that the current single molecule approach of individual phytocannabinoids remains the predominant pharmaceutical development strategy [50], for complex diseases such

as ASD, multi-target strategies and botanical drug development may be an effective treatment strategy.

Evidence from animal studies suggests that CBD positively affects various physiological responses. However, there is limited evidence from clinical trials to support the potential therapeutic benefits of this non-psychoactive phytocannabinoid for pediatric neurodevelopmental disorders [51]. Only three randomised controlled studies have been published on medicinal cannabis use in children with ASD; two were short-term [58, 59], and the other only reported sleep outcomes [60]. Additionally, most studies on this topic are openlabel observational or retrospective design [52-57].

This single centre, phase I/II open-label study aimed to evaluate the efficacy and safety of a novel oil-based full-spectrum medicinal cannabis plant extract with 0.08% THC (NTI-164) in children with ASD over four weeks of daily treatment.

Materials and methods

Study design and participants

The study design was a single-centre open-label trial to evaluate the safety and efficacy of a novel full-spectrum medicinal cannabis plant extract containing only 0.08% THC (NTI-164) in children with ASD over four weeks of daily treatment. The trial enrolled 18 eligible male and female paediatric patients aged 8-17 with Level 2 or 3 ASD based on the Autism

Diagnostic Observational Schedule (ADOS-2) criteria [61] between 4 February 2022 and 8 September 2022.

This study was approved by the Monash Health Human Research Ethics Committee (RES-21-0000-177A) and registered with the Australian and New Zealand Clinical Trial Registry (Trial ID: ACTRN12621000760875).

Study objectives

The primary objective was to evaluate the safety and tolerance of NTI-164 in children with ASD throughout the trial. In addition to assessment questionnaires, safety data were collected through laboratory tests, including full blood examination, liver and renal function tests performed at screening and at the beginning of week five during hospital visits. The secondary objective was to assess the efficacy of NTI-164 in treating ASD-associated symptoms. Efficacy data were collected through physician, parent (or caregiver) and schoolaged participant-reported questionnaires at two designated time points. This study explored the effect of NTI-164 on core behavioural symptoms of children with ASD and associated symptoms, including irritability, hyperactivity, mood, anxiety, sleep disorders and self-stimulation.

Pharmacological Intervention

The chemical composition profile of the investigational product NTI-164 consisted of 62% Cannabidiolic Acid (CBDA), 14% Cannabidiol (CBD), 0.44% Cannabigerolic Acid (CBGA), 0.06% Cannabidivarin (CBDV) and 0.08% Tetrahydrocannabinol (THC). The

investigational product was provided and dispensed in a glass jar as a 53 mg/mL oil-based solution ready for self-administration at home. During the initial hospital visit (baseline), the participants received the packaged investigational product with instructions. Participants were also given access to a web app (Caspio Participant Portal) to record daily drug administration.

Several lines of evidence from controlled trials have shown the effectiveness of CBD at a dose of 20 mg/kg in managing seizures [62-64]. Therefore, this dose was used in the current study, with participants starting treatment on a daily dose of 5mg/kg of NTI-164 at baseline. To minimise the risk of undesired side effects, the dose was increased by 5mg/kg weekly to reach the maximum tolerated daily dose or 20 mg/kg daily. The daily dose was calculated by multiplying the dosage by each patient's weight and then dividing by the concentration of CBDA in the oil (53mg/mL). This provided a total daily volume in mL divided into twice daily doses. Protocol adherence was assessed by the accountability of returned investigational product and packaging at the end of the four weeks.

Outcome measures

Primary outcome measure

The primary endpoint was safety and tolerability of NTI-164 treatment as determined by monitoring and assessment through standard laboratory tests of full blood examination, liver and renal function tests, as well as vital signs in addition to physician and parent (or caregiver) reported questionnaires completed at baseline and after completion of 4 weeks of treatment.

Adverse events were assessed and evaluated by designated study staff through discussions with the participant at the scheduled study visit after the end of four weeks, as well as through phone contacts and clinically significant laboratory results. Whenever an adverse

event was reported during treatment at home, the Principal Investigator was notified immediately via the online portal. The Principal Investigator or a designated study staff member promptly followed all adverse events. Documentation of adverse events included details of the event, dates and times, severity, duration and possible relationship to the investigational product.

Secondary outcome measure

189

190

191

192

193

194

195

196

197

198

199

200

- The efficacy assessments included the administration of both quantitative and qualitative ASD-related questionnaires, with the first four scales described below completed by both the caregiver and clinician. The selected questionnaires were specific to various comorbidities associated with autism spectrum disorder. The purpose was to evaluate the impact of NTI-164 on symptoms associated with autism spectrum disorder. All scales were administered at baseline (week 1) and post-baseline (week 5).
- 1. Clinical Global Impression of Improvement for the Caregiver (CGI-I-Ca) [65]: This is a 7 point scale measuring symptom change from baseline.
- 203 2. Clinical Global Impression of Improvement for the Clinician (CGI-I-C) [65]: This is a 7-204 point scale measuring symptom change from baseline.
- 3. Caregiver Global Impression of Change (CGI-C) Target Behaviour [65]: Reflects clinician's
 impression of behaviour change on a 7-point scale ranging from 1=not at all to 7=very severe
 problem.
- 4. Clinical Global Impression of Change in Attention (CGI-CA) [65]: Reflects clinician's impression of change in attention on a 7-point scale ranging from 1=not at all to 7=very severe problem.

211	5. Clinical Global Impression of Severity of Illness (CGI-S) [65]: Reflects clinician's
212	impression of severity of illness on a 7-point scale ranging from 1=not at all to 7=among the
213	most extremely ill.
214	6. Anxiety Scale for Children - autism spectrum disorder – Parent Version (ASC-ASD-P) [66]:
215	Parent/Caregiver form was developed to detect anxiety symptoms in youth with ASD. They
216	are composed of four subscales: Performance Anxiety, Uncertainty, Anxious Arousal, and
217	Separation Anxiety. Items are rated on a 4-point scale (0=never and 3=always). Subscales sum
218	to equal a total score.
219	7. Anxiety Scale for Children - autism spectrum disorder – Child Version (ASC-ASD-C) [66]::
220	Child form developed to detect symptoms of anxiety in youth with ASD. Composed of the four
221	Subscales: Performance Anxiety, Uncertainty, Anxious Arousal, and Separation Anxiety.
222	Items are rated on a 4-point scale (0=never and 3=always). Subscales sum to equal a total
223	anxiety score, with lower scores indicating a decreased level of anxiousness. The total score
224	ranged from 6 to 55 and 3 to 50 out of a possible maximum score of 72 for the ASC-ASD-P
225	and ASC-ASD-C version, respectively.
226	8. Sleep Disturbance Scale for Children (SDSC) [67]: Includes the six subscales of Disorders
227	of Initiating and Maintaining Sleep, Sleep Breathing Disorders, Disorders of Arousal, Sleep
228	Wake Transition Disorders, Disorders of Excessive Somnolence, and Sleep Hyperhydrosis.
229	Items are rated on a 5-point scale where 1=never and 5=always (daily). Subscale scores sum to
230	equal a total sleep score, with a higher score reflecting more sleep-related problems.

Study procedures

The study schedule of procedures and assessments is presented in Table 1. Participants were recruited through Monash Children's Hospital (MCH) in Melbourne, Australia. Potential participants attended a screening visit for assessment based on study selection criteria (See Supplementary information, File 1) and were provided with the Participant Information Sheet and Consent Form. After obtaining written informed consent from caregivers, eligible participants underwent a physical assessment, including vital signs, anthropometric measurements, full blood examination, liver and renal function tests as part of the screening process. In case of restrained compliance with blood sample collection, analgesia with nitrous oxide was administered by a trained staff member. At this visit, a parent survey was obtained concerning the medical and family history of the participating child, including current attendance at specific programs or health service utilisation.

Table 1. Study schedule of procedures and assessments for the 28 day open-label trial.

Assessments	Screeni	Visit 1/	Visit 2 /
Assessments	ng	Week 1	Week 5
Day	-14 to -1	1	29
CGI-I-Ca Baseline		X	
CGI-I-Ca Post-baseline			X
CGI-I-C Baseline		X	
CGI-I-C Post-baseline			X
CGI-C Baseline		X	
CGI-C Post-baseline			X
CGI-CA Baseline		X	
CGI-CA Post-baseline			X
CGI-S		X	X

A	Screeni	Visit 1/	Visit 2 /	
Assessments	ng	Week 1	Week 5	
SDSC		X	X	
ASC-ASD-P		X	X	
ASC-ASD-C		X	X	
Parent survey	X			
Medical history	X			
Concomitant medications	X	X	X	
Physical examination (including vital signs)	X	X	X	
Weight measurement	X	X	X	
Height measurement	X			
FBE	X		X	
LFT	X		X	
UEC	X		X	
Dispense study medication		X	X	
Collection returned IP			X	
Drug administration		Xda	nilyX	
Caspio Participant Portal (web app)		XX		
Caspio Physician Portal	X	v	v	
(web app)	A	X	X	
Evaluation measures		X	X	
Safety outcome measure		X	X	

Aggaggmantg	Screeni	Visit 1/	Visit 2 /
Assessments	ng	Week 1	Week 5
Adverse events		X	X
Accountability		X	X

Abbreviations ASC-ASD-C: Anxiety Scale for Children - Autism Spectrum Disorder; ASC-ASD-P: Anxiety Scale for Children - Autism Spectrum Disorder - Parent Versions; CGI-I-Ca: Clinical Global Impression of Improvement for the Caregiver; CGI-I-C: Clinical Global Impression of Improvement for the Clinician; CGI-C: Caregiver Global Impression of Change; CGI-CA: Caregiver Global Impression of Change in Attention; CG-S: Clinical Global Impression—Severity; SDSC: Sleep Disturbance Scale for Children.

At the first visit in week 1 (baseline), participants completed all the required questionnaires and the first daily dose of 5mg/kg of the investigational product NTI-164 was administered. The participant was monitored for 2 hours for any immediate adverse events. Participants who did not report any adverse events were dispensed with NTI-164 for four weeks and instructed to administer the daily volume orally over two doses. Instructions were provided on administering increasing the dose of the product to a maximum of 20mg/kg/day from home. Participants were also trained to use the study web app (Caspio Participant Portal) to record drug administrations, report adverse events, and complete questionnaires from home.

Once the four-week treatment was completed, at the start of the week 5 visit (post-baseline), participants underwent the same set of laboratory tests and physical assessments as before and completed all specified post-baseline questionnaires. To ensure adherence to study protocol and accountability, returned product and packaging were collected and recorded at this visit.

Statistical analysis

The safety and tolerability were assessed by recording the frequency and severity of reported adverse events by all treated participants. The distribution was analysed using patient demographics, laboratory values and vital signs. Given the small sample size of this study, descriptive statistical analyses of the mean score, mean change, and Standard Deviation (SD) were performed on quantifiable outcome measures. The Wilcoxon Signed-Rank Test and the Paired t-test were used to assess the statistical significance of the analysed data sets. The final statistical analysis included all participants completing the initial four week treatment phase. The CGI-S scale was used to analyse the therapeutic effect of NTI-164 and its changes to the severity of illness. The ASC-ASD-C and ASC-ASD-P questionnaires were used to assess anxiety across four sub-domains, and the SDSC was used to assess changes to sleep from baseline and at the end of the 4 weeks. Clinical Global Impression scales were used to analyse efficacy by measuring symptom change from baseline. Each CGI survey uses the same 7-point scale to measure symptom change from baseline: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse and Very much worse.

Results

Participant characteristics

Fourteen of the 18 participants enrolled in the study completed the full treatment. One patient withdrew before treatment began, and three patients discontinued during treatment. Most of the treated patients were male (9/14), Caucasian (12/14), and had an average age of 13.4 years (ranging from 10-17 years). All active patients were diagnosed with ASD Level 2/3 and were evaluated at baseline as "Mildly ill" (4 patients), "Moderately ill" (4 patients),

"Markedly ill" (3 patients), or "Severely ill" (3 patients), according to the CGI-Severity of Illness scale. The average daily dose for treated patients was 16.7 mg/kg/day. About 64% of patients could tolerate the maximum dose of 20 mg/kg/day, while 36% tolerated a maximum daily dose ranging between 6 mg/kg/day and 19 mg/kg/day.

Safety and tolerability

Eight participants experienced ten mild to moderate adverse events, totalling 17 adverse reports during treatment. One participant discontinued treatment. The most frequent side-effect was gastrointestinal symptoms reported by a third of participants (36%). None of these side effects were severe enough to significantly interfere with the patient's functioning. Most patients were advised to rest to treat these transient adverse effects (Table 2). No serious adverse events or deaths related to the investigational drug were reported during the study. The safety data indicated that NTI-164 at 5, 10, 15 and 20 mg/kg administered in two daily doses is safe and well-tolerated in this study population. Laboratory values provide further safety support. No changes were observed in patients' full blood examination, liver function or kidney function tests (Table 3). Also, no changes were observed to the vital signs of active patients during treatment, further corroborating that NTI-164 was well-tolerated.

Table 2. Reported adverse events during the trial.*

Adverse Event	Total No. of	Frequency	Treatment	
	Reports	(%)		
Abdominal pain	3	14%	Rest	
Lack/loss of appetite	3	14%	None	
Diarrhoea	2	9%	None	
Vomiting	2	9%	None	

Lethargy	2	9%	Rest
Hypoglycaemia	1	5%	None
Rashes**	1	5%	Zyrtec for
			itchiness
Itchiness without	1	5%	Warm shower
rash			
Sore Throat	1	5%	Rest
Upper Respiratory	1	5%	Treated by
Tract Infection			doctor

^{*} Two participants were excluded as one had ingrown nail infection and one had knee surgery

307

308

309

Table 3. Evaluation of clinical laboratory parameters (n=12) at timepoint 1 (screening visit)
and timepoint 2 (start of week 5).

Parameter	,	Timepoint 1	1		Timepoint 2		
	Mean	Minimu	Maxim	Mean	Minimu	Maximu	Change
		m	um		m	m	
Sodium	139	136	142	139	137	141	-1
Potassium	4.3	3.8	4.8	4.4	3.7	4.8	0
Chloride	104	102	108	104	101	106	1
Bicarbonat	25	19	29	25	22	30	0
e							
Urea	4.6	3.1	6.1	4.1	2.6	5.9	0.2

^{**} This participant discontinued during the treatment and did not complete the study

Creatinine	47	35	68	50	36	73	3
Glucose	4.9	3.3	6.3	4.5	2	7.1	-0.1
ALP	287	101	438	280	82	424	-23
GGT	17	11	25	15	8	29	-0.5
ALT	24	5	57	26	6	48	0
Total	11	4	40	9	4	14	0
Bilirubin							
Haemoglob	133	115	147	133	119	144	2
in							
RBC	4.69	4.1	5.34	4.74	4.36	5.11	0.11
MCV	83	75	90	84	77	90	1.5
МСН	32.4	25.2	86	28.2	25.5	30.8	0.3
МСНС	342	331	349	337	330	348	2
RDW	13.5	12.4	16.7	13.7	12.6	16.9	0.3
WCC	7.6	4.8	14.6	7.0	4.4	11.4	-1
Neutrophil	3.94	1.7	8.69	3.47	1.79	4.7	-0.66
S							
Lymphocyt	2.66	1.45	6.16	2.54	1.15	4.73	-0.035
es							
Monocytes	0.54	0.31	0.79	0.55	0.35	1.05	-0.06
Eosinophil	0.45	0.1	1.24	0.41	0.03	1.14	-0.05
S							
Basophils	0.05	0	0.09	0.06	0	0.1	0.02
Platelets	294	190	413	301	214	422	-13.5

Abbreviations. ALP: Alkaline Phosphatase; ALT: Alanine Transaminase; GGT: Gamma-Glutamyl Transferase; MCH: Mean Corpuscular Haemoglobin; MCHC: Mean Corpuscular Haemoglobin Concentration; MCV: Mean Corpuscular Volume; RBC: Red blood cell; RDW: Red Cell Distribution Width; WCC: White Cell Count.

Analysis of therapeutic efficacy

Clinical Global Impression-Severity (CGI-S)

The Clinical Global Impression-Severity (CGI-S) scale was used to assess global improvement, the severity of illness, and the efficacy index based on drug effect only (Table 4). Of the 14 treated patients, 13 (93%) showed symptomatic improvement. 64% of these patients showed a global improvement of 'Much improved', 29% showed 'Minimally improved', and only one patient (7%) had 'No change' (Figure 1).

Fig 1. Clinical Global Impression – Global Improvement.

Table 4. Symptom change scores for each Clinical Global Impression (CGI) scale.

CGI Assessment	Symptom Change from Baseline					
	1. Very	2. Much	3.	4. No		
	much	improved	Minimally	change		
	improved		improved			
CGI of Severity of Illness	0	9 (64%)	4 (29%)	1 (7%)		
(CGI-S)						
CGI of Improvement for the	1 (7%)	7 (50%)	4 (29%)	2 (14%)		
Caregiver						

(CGI-I-Ca)				
CGI of Improvement for the	1 (7%)	4 (29%)	7 (50%)	2 (14%)
Clinician				
(CGI-I-C)				
CGI of Change in Target	2 (14%)	4 (29%)	3 (21%)	5 (36%)
Behaviour				
(CGI-C)				
CGI of Change in Attention	0	3 (21%)	4 (29%)	7 (50%)
(CGI-CA)				

At baseline, the average rating for the severity of illness was 4.4, which was reduced to an average rating of 3.6 after 28 days of NTI-164 treatment (Figure 2). The mean difference of CGI-S between 28 days of treatment and baseline was -0.714 (95% CI: -1.332, -0.097, p=0.027), with the Wilcoxon Signed-Rank Test statistic showing a significant difference of -15 (p=0.047).

Fig 2. Clinical Global Impression – Severity of Illness.

At the end of the study, 14% of active patients receiving daily treatment with NTI-164 demonstrated the second highest possible efficacy index of 2, indicating marked therapeutic effects with side effects that did not significantly interfere with functioning. Clinicians rated NTI-164 to have a moderate therapeutic effect (efficacy index of 5 or 6) in 72% of treated patients, with half having no side effects and the other half having side effects that did not significantly interfere with functioning. A minimal therapeutic effect (efficacy index of 9) was observed in 7%, and an unchanged therapeutic effect (efficacy index of 13) in just one participant (Figure 3).

Anxiety symptoms

To measure anxiety symptoms in treated participants with ASD, the Anxiety Scale for Children, both -Parent and -Child versions (ASC-ASD) were used. The mean scores, Wilcoxon Signed-Rank test, and corresponding p values for both ASC-ASD-P and ASC-ASD-C versions are summarised and reported in Table 5. The total score of the Anxiety Scale for Children was reduced in more than half of both parents (62%) and children (54%) scales after four weeks of treatment. During the same period, nearly a quarter of parents (23%) and a third of children (36%) reported increased levels of anxiousness, while 15% and 9% of parents and children reported no change, respectively. The mean change for the total score of the ASC-ASD parent version was significantly reduced by 14% (p=0.0414), while the child version of the scale was non-significantly reduced by 6.8% after four weeks of treatment. The most frequently endorsed items on the ASC-ASD-P and ASC-ASD-C were from the Uncertainty (mean change 15.6%) and Separation Anxiety (25.4%) subscales post-treatment, respectively (Table 5).

Table 5. Anxiety assessment for Children. Results are expressed as Mean \pm SD

Assessment	Baseline	Week 5	Mean	Wilcoxon signed
			change	rank test
				(P value)
Anxiety Scale for Childre	en – Parent Vers	ion (ASD-ASC-A	P) n=11	
Total ASC-ASD	31.5± 14.7	27.1± 12.9	-4.4	47.5 (0.0414)
Performance Anxiety	7.5± 4.4	6.5± 3.7	-1.0	25.5 (0.0474)
Anxiety Arousal	4.0± 3.9	3.9± 3.2	-0.1	15.0 (0.865)

Separation Anxiety	5.3 ± 4.1	4.9 ± 4.0	-0.4	17.5 (0.139)			
Uncertainty	14.1± 5.8	11.9± 4.4	-2.2	47.0 (0.0459)			
Anxiety Scale for Children – Child Version (ASD-ASC-C) n=9							
Total ASC-ASD	30.9± 10.1	28.8± 13.3	-2.1	33.0 (0.213)			
Performance Anxiety	6.6± 3.9	6.1± 3.3	-0.5	21.0 (0.206)			
Anxiety Arousal	4.3± 3.7	5.4± 3.1	1.1	11.5 (0.360)			
Separation Anxiety	6.7± 3.6	5.0± 4.4	-1.7	37.0 (0.0834)			
Uncertainty	13.3± 4.9	12.2± 5.5	-1.1	26.0 (0.258)			

Sleep quality and sleep disturbances

To assess changes to sleep quality, the SDSC questionnaire was used. Of the 14 study participants, 11 children completed sleep assessment before and after 28 days of treatment. Although the total sleep score decreased from baseline to post-treatment, it was not statistically significant. The scores for all sleep outcomes except Disorders of excessive somnolence improved non-significantly from baseline to post-treatment (Table 6).

Table 6 Sleep Disturbances Scale for Children (SDSC). Results are expressed as Mean \pm SD

Sleep Domains	Baseline	Week 5	Mean	Wilcoxon
			difference	signed-rank
				test
				(p value)
Total Score (n=11)	50.5± 17.1	48.4± 13.4	-2.0	29 (0.721)
Disorder of initiating &	17.6 ± 6.9	16.4 ± 6.3	-1.2	24.5 (0.811)
maintaining sleep				

Sleep breathing disorders	6.0 ± 3.0	5.5 ± 2.3	-0.5	16 (0.234)
Disorders of arousal	4.0± 1.6	3.9± 1.2	-0.1	3 (1)
Sleep-wake transition	11.9± 4.4	11.2± 3.3	-0.7	15 (0.343)
disorders				
Disorders of excessive	8.3± 3.3	9.1± 3.7	0.8	13 (0.481)
somnolence				
Sleep hyperhydrosis	2.7± 1.2	2.4± 0.9	-0.3	5 (0.285)

Discussion

The current pharmacological and behavioural interventions are limited in treating a considerable portion of children with ASD-related symptoms due to a lack of efficacy or adverse side effects that interfere with daily functioning. Therefore, there is an urgent need for a more concerted effort in clinical research to develop effective and safer therapies for addressing ASD associated comorbid symptoms. While the available evidence from controlled studies on the role of medicinal *Cannabis sativa* in the management of children with ASD is limited, a large body of evidence from preclinical studies has demonstrated the positive effects of cannabinoids in the modulation of a wide range of biological responses in particular neurodevelopmental processes. Furthermore, emerging evidence from recent observational studies [53-55, 57] has indicated that a synergistic and entourage pharmacological effect of *Cannabis sativa* derivatives can contribute to improved ASD-related symptoms and comorbidities in children. Therefore, this study sought evidence for the safety and efficacy of NTI-164, a full spectrum botanical product, per the entourage effect in managing ASD comorbid symptoms in paediatric patients. The findings demonstrate that NTI-164 is safe and

well-tolerated in children up to 20 mg/kg daily dose with transient side effects that did not significantly interfere with the general functioning of treated patients.

Furthermore, NTI-164 exhibited statistically significant efficacy in improving ASD core and associated symptoms after four weeks of treatment. In particular, following NTI-164 treatment, targeted behavioural problems were much improved or very much improved in nearly half of the patients. More than half of caregivers and children also reported consistent improvements in the anxiety level of participants. Despite the limited sample size with completed sleep data, the overall direction of change indicated improved sleep outcomes and warrants further longitudinal evaluation. Based on these promising findings, we have initiated an extended treatment open-label trial for 57 weeks to assess long-term NTI-164 safety and efficacy in children and adolescents with ASD and related comorbidities.

Impact of full-spectrum cannabis extract on ASD core symptoms

The safety profile and tolerability of NTI-164 were favourable in the patients who completed treatment consistent with previous clinical studies that used whole plant medicinal cannabis extract to treat children and adolescents with ASD-related symptoms [52-58]. The most frequent side-effect in our cohort was related to gastrointestinal symptoms, which were transient and improved with rest by the end of the treatment phase. However, the majority of clinical studies using full-spectrum cannabis extract for the treatment of children with ASD reported mild or transient adverse events frequently related to sleep disturbances [52-55, 58, 59], anxiety or irritability symptoms [52, 55, 57, 58] which were absent in our cohort. This might be due to different strains with variable composition of phytocannabinoids and higher doses of THC than our full-spectrum medical cannabis extract with negligible THC (0.08%). Alternatively, side-effects not observed in our study might be due to other studies, including

primarily children diagnosed with severe ASD, since sleep disturbances have been reported as a side-effect of isolated CBD treatment in children with severe behavioural problems [68]. In addition, several studies have found that the severity of ASD core symptoms is associated with the severity of sleep disturbances in younger children [60, 69, 70]. Compared to other clinical studies that included children as young as four years old, our active patients were much older (10-17 years). The effect of different compositions of phytocannabinoids and THC levels in full-spectrum extracts on the severity of ASD symptoms in younger children, therefore, requires further investigation.

This is the first study of full-spectrum cannabis extract treatment in children with ASD to report subjective measures of adverse events and objective measures of biochemical analysis and vital signs following treatment. In a prospective cohort study of biochemical safety analysis of an oil-based full-spectrum cannabis product, all parameters were within the normal range in children with ASD after three months of treatment [71]. However, this study did not report an evaluation of adverse events or vital signs following treatment. Notably, a recent randomised controlled feasibility study reported no significant abnormal biochemical test results after eight weeks of therapy with isolated CBD in children with severe behavioural problems and intellectual disability [68].

In our study, overall daily treatment with NTI-164 for four weeks significantly improved symptoms in 93% of active patients, with nearly two-thirds of children rated by clinicians to exhibit moderate effects following treatment. Similarly, several cohort studies in children using full-spectrum products have demonstrated significant overall improvement in ASD symptoms reported by parents [52-54, 56] and clinicians [55, 57]. Specifically, we found that almost half of treated children with ASD showed reduced disruptive behaviour consistent with other studies that have demonstrated improvement in behavioural problems ranging from 32% to 90%, including adaptive behaviours, self-injury and hyperactivity [53, 57, 59]. Social

interaction and communication have also significantly improved following treatment with full-spectrum cannabis extract in children with ASD-related symptoms [52, 55-57]. In addition, two randomised controlled trials have shown that cannabinoid treatment, compared to placebo in children, was safe with acceptable tolerability and effective at reducing ASD-associated disruptive behaviours [58, 59]. However, compared to pure cannabinoids, there was no apparent difference with improvements observed for treatment with whole-plant extract after 12 weeks. The clinical benefits of the entourage effects of our cannabis strain compared to purified cannabinoids remain to be further explored in longitudinal controlled studies.

Impact of full-spectrum cannabis extract on ASD-related comorbidities

In addition to improvements in behavioural outcomes, a recent systematic review of the evidence for medicinal cannabis in ASD treatment found benefits for a broad range of comorbidities, including cognition, anxiety and sleep disturbances in adults and children [72]. Consistent with previous studies [52-54], we also found that after four weeks of treatment with full-spectrum cannabis extract, anxiety symptoms were reduced in more than half of our cohort based on both parent and children reported anxiety questionnaires. In particular, the parent-rated total scores and the performance anxiety and uncertainty subscales significantly improved for children with ASD. However, the magnitude of improvement on child-rated outcome measures did not reach statistical significance despite the direction of change, suggesting reduced anxiety symptoms in half of the treated patients. This rating discrepancy might be due to differences in perceptions of anxiety for children with ASD and their parents with the severity of ASD symptoms reportedly contribute to the disparity in parent-child anxiety rating where higher severity levels were shown to be associated with the tendency for parent ratings to exceed child anxiety rating [73]. Nevertheless, this finding highlights the clinical implication

of self-report rating to inform areas of concern for continued assessment of anxiety symptoms in children with ASD.

While previous prospective cohort studies have reported treatment with whole plant cannabis extract of various strains significantly improved sleep outcomes in children with ASD [53-55], a recent randomised controlled trial did not find any difference between cannabinoid treatment and placebo in sleep parameters after 12 weeks [60]. We also did not find significant improvement in any of the sleep domains as measured by a validated sleep questionnaire. These inconsistencies could be due to differences in treated participant characteristics, especially level of ASD severity, age, instruments used to measure sleep or strain of cannabis with various phytocannabinoid composition. In addition, since the previous studies that reported improved sleep outcomes were over several months, this may indicate the need for a longer period before any benefit in sleep quality can be observed from treatment with cannabinoid extract.

These findings support the safety and efficacy of full-spectrum products and promising entourage effects of cannabinoids in treating children with ASD-related symptoms.

Limitations

There were several limitations in this study. Since our study was an open-label design to collect preliminary data on the safety and efficacy of NTI-164 treatment of symptoms in children with ASD, no control group was included. However, the addition of objective measures of vital signs and biochemical analysis to subjective reports of adverse events further strengthened the NTI-164 safety profile in treated children with ASD. Nevertheless, further research for long-term evaluation of safety data of NTI-164 botanical product for the treatment

of children with ASD symptoms, especially in terms of interaction with concomitant medications, is needed.

Given that the sample size was small, evaluation of the impact of NTI-164 treatment on subgroups of children with various ASD severity was not possible. Although data was collected on concomitant medications prescribed for ASD-related comorbidities, this study was not powered to determine the impact of chronic medication on treatment response. Also, we only used subjective measures of sleep outcomes, and future studies should include actigraphy or polysomnography together with sleep diaries as objective measurements of sleep quality.

Conclusions

This open-label study provided preliminary efficacy and safety data on a novel botanical formulation of phytocannabinoids in treating symptoms in children with ASD and associated comorbidities. Results indicate that NTI-164 is safe and well-tolerated, with significant efficacy in improving disruptive behaviours and reducing anxiety in this Pediatric cohort. The findings of this study further contribute to the accumulating evidence in favour of whole plant cannabis extracts, with most participants reporting a clinically meaningful change in ASD-related symptoms and associated anxiety. Despite the small sample size, objective safety analysis together with converged evidence from standardised clinician, parent and child-reported questionnaires with respect to overall improvement strengthen the evidence for the benefit of full-spectrum cannabis extract in the treatment of children with ASD-related symptoms. Furthermore, these results are consistent with other prospective cohort studies of

full-spectrum cannabis extract and support further evaluation of the clinical benefits of whole
plant extracts in rigorous placebo-controlled trials of longer duration in this patient population.

502

503

504

References

- 1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: American Psychiatric Publishing; 2013.
- Lord C, Brugha TS, Charman T, Cusack J, Dumas G, Frazier T, et al. Autism
 spectrum disorder. Nat Rev Dis Primers. 2020;6(1):1-23.
- Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric
 disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated
 factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry.
 2008;47(8):921-9.
- 513 4. Evers K, Maljaars J, Schepens H, Vanaken GJ, Noens I. Conceptualization of quality 514 of life in autistic individuals. Dev Med Child Neurol. 2022;64(8):950-6.
- 515 5. Van Heijst BF, Geurts HM. Quality of life in autism across the lifespan: A meta-516 analysis. Autism. 2015;19(2):158-67.
- 517 6. Salari N, Rasoulpoor S, Rasoulpoor S, Shohaimi S, Jafarpour S, Abdoli N, et al. The 518 global prevalence of autism spectrum disorder: a comprehensive systematic review and meta-519 analysis. Ital J Pediatr 2022;48(1):1-16.

- 520 7. Kang L, Liu J, Liu Y, Liang W, Yang F, Liu M. Global, regional, and national disease
- burden of autism spectrum disorder among children under 5 years from 1990 to 2019: An
- analysis for the Global Burden of Disease 2019 Study. Asian Journal of Psychiatry.
- 523 2023;79:103359. doi: https://doi.org/10.1016/j.ajp.2022.103359.
- 8. Bieleninik Ł, Gold C. Estimating components and costs of standard care for children
- with autism spectrum disorder in Europe from a large international sample. Brain Sci.
- 526 2021;11(3):340.
- 527 9. Cakir J, Frye RE, Walker SJ. The lifetime social cost of autism: 1990–2029. Res
- 528 Autism Spectr Disord. 2020;72:101502. doi: 10.1016/j.rasd.2019.101502.
- 529 10. Blaxill M, Rogers T, Nevison C. Autism Tsunami: the Impact of Rising Prevalence on
- the Societal Cost of Autism in the United States. J Autism Dev Disord. 2022;52(6):2627-43.
- 531 doi: 10.1007/s10803-021-05120-7.
- 532 11. Aishworiya R, Valica T, Hagerman R, Restrepo B. An Update on
- Psychopharmacological Treatment of Autism Spectrum Disorder. Neurotherapeutics.
- 534 2022;19(1):248-62. doi: 10.1007/s13311-022-01183-1.
- 535 12. Anagnostou E. Clinical trials in autism spectrum disorder: evidence, challenges and
- future directions. Curr Opin Neurol. 2018;31(2):119-25.
- 13. Persico AM, Ricciardello A, Lamberti M, Turriziani L, Cucinotta F, Brogna C, et al.
- The pediatric psychopharmacology of autism spectrum disorder: A systematic review Part I:
- The past and the present. Prog Neuropsychopharmacol Biol Psychiatry. 2021;110:110326.
- doi: https://doi.org/10.1016/j.pnpbp.2021.110326.

- 541 14. Edgcomb JB, Zima B. Medication Adherence Among Children and Adolescents with
- Severe Mental Illness: A Systematic Review and Meta-Analysis. J Child Adolesc
- Psychopharmacol. 2018;28(8):508-20. Epub 2018/07/25. doi: 10.1089/cap.2018.0040. PMID:
- 544 30040434.
- 545 15. Cheroni C, Caporale N, Testa G. Autism spectrum disorder at the crossroad between
- genes and environment: contributions, convergences, and interactions in ASD developmental
- pathophysiology. Mol Autism. 2020;11(1):69. doi: 10.1186/s13229-020-00370-1.
- 548 16. Jeste SS, Geschwind DH. Disentangling the heterogeneity of autism spectrum
- disorder through genetic findings. Nat Rev Neurol. 2014;10(2):74-81. Epub 2014/01/29. doi:
- 550 10.1038/nrneurol.2013.278. PMID: 24468882.
- 551 17. Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid
- system in neurological disorders. Nat Rev Neurol. 2020;16(1):9-29. Epub 2019/12/14. doi:
- 553 10.1038/s41582-019-0284-z. PMID: 31831863.
- 554 18. Melis M, Greco B, Tonini R. Interplay between synaptic endocannabinoid signaling
- and metaplasticity in neuronal circuit function and dysfunction. Eur J Neurosci.
- 556 2014;39(7):1189-201. Epub 2014/04/10. doi: 10.1111/ejn.12501. PMID: 24712998.
- Wei D, Lee D, Cox CD, Karsten CA, Peñagarikano O, Geschwind DH, et al.
- Endocannabinoid signaling mediates oxytocin-driven social reward. Proc Natl Acad Sci U S
- 559 A. 2015;112(45):14084-9. Epub 2015/10/28. doi: 10.1073/pnas.1509795112. PMID:
- 560 26504214.
- 561 20. Chakrabarti B, Persico A, Battista N, Maccarrone M. Endocannabinoid Signaling in
- Autism. Neurotherapeutics. 2015;12(4):837-47. Epub 2015/07/29. doi: 10.1007/s13311-015-
- 563 0371-9. PMID: 26216231.

- 564 21. Marco EM, Laviola G. The endocannabinoid system in the regulation of emotions
- throughout lifespan: a discussion on therapeutic perspectives. J Psychopharmacol.
- 566 2012;26(1):150-63. Epub 2011/06/23. doi: 10.1177/0269881111408459. PMID: 21693551.
- 22. Zou M, Li D, Li L, Wu L, Sun C. Role of the endocannabinoid system in neurological
- disorders. Int J Dev Neurosci. 2019;76:95-102. Epub 2019/03/13. doi:
- 569 10.1016/j.ijdevneu.2019.03.002. PMID: 30858029.
- 570 23. Pietropaolo S, Marsicano G. The role of the endocannabinoid system as a therapeutic
- target for autism spectrum disorder: Lessons from behavioral studies on mouse models.
- 572 Neurosci Biobehav Rev. 2022;132:664-78. Epub 2021/11/24. doi:
- 573 10.1016/j.neubiorev.2021.11.031. PMID: 34813825.
- 574 24. Zamberletti E, Gabaglio M, Woolley-Roberts M, Bingham S, Rubino T, Parolaro D.
- 575 Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal
- 576 Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure
- in Rats. Front Cell Neurosci. 2019;13:367. Epub 2019/08/27. doi: 10.3389/fncel.2019.00367.
- 578 PMID: 31447649.
- 579 25. Kerr DM, Downey L, Conboy M, Finn DP, Roche M. Alterations in the
- endocannabinoid system in the rat valproic acid model of autism. Behav Brain Res.
- 581 2013;249:124-32. Epub 2013/05/07. doi: 10.1016/j.bbr.2013.04.043. PMID: 23643692.
- 582 26. Aran A, Eylon M, Harel M, Polianski L, Nemirovski A, Tepper S, et al. Lower
- circulating endocannabinoid levels in children with autism spectrum disorder. Mol Autism.
- 584 2019;10(1):2. doi: 10.1186/s13229-019-0256-6.

- 585 27. Karhson DS, Krasinska KM, Dallaire JA, Libove RA, Phillips JM, Chien AS, et al.
- Plasma anandamide concentrations are lower in children with autism spectrum disorder. Mol
- 587 Autism. 2018;9:18. Epub 2018/03/23. doi: 10.1186/s13229-018-0203-y. PMID: 29564080.
- 588 28. Siniscalco D, Sapone A, Giordano C, Cirillo A, de Magistris L, Rossi F, et al.
- Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear
- cells of children affected by autistic disorders. J Autism Dev Disord. 2013;43(11):2686-95.
- 591 Epub 2013/04/16. doi: 10.1007/s10803-013-1824-9. PMID: 23585028.
- 592 29. Schiavi S, Manduca A, Carbone E, Buzzelli V, Rava A, Feo A, et al. Anandamide and
- 2-arachidonoylglycerol differentially modulate autistic-like traits in a genetic model of autism
- based on FMR1 deletion in rats. Neuropsychopharmacology. 2022. Epub 2022/09/17. doi:
- 595 10.1038/s41386-022-01454-7. PMID: 36114286.
- 596 30. Wei D, Dinh D, Lee D, Li D, Anguren A, Moreno-Sanz G, et al. Enhancement of
- 597 Anandamide-Mediated Endocannabinoid Signaling Corrects Autism-Related Social
- 598 Impairment. Cannabis Cannabinoid Res. 2016;1(1):81-9. Epub 2016/02/01. doi:
- 599 10.1089/can.2015.0008. PMID: 28861483.
- 600 31. Qin M, Zeidler Z, Moulton K, Krych L, Xia Z, Smith CB. Endocannabinoid-mediated
- 601 improvement on a test of aversive memory in a mouse model of fragile X syndrome. Behav
- Brain Res. 2015;291:164-71. Epub 2015/05/17. doi: 10.1016/j.bbr.2015.05.003. PMID:
- 603 25979787.
- Arnold JC, McCartney D, Suraev A, McGregor IS. The safety and efficacy of low
- oral doses of cannabidiol: An evaluation of the evidence. Clinical and translational science.
- 606 2023;16(1):10-30.

- 607 33. Chesney E, Oliver D, Green A, Sovi S, Wilson J, Englund A, et al. Adverse effects of
- cannabidiol: a systematic review and meta-analysis of randomized clinical trials.
- Neuropsychopharmacology. 2020;45(11):1799-806. Epub 2020/04/09. doi: 10.1038/s41386-
- 610 020-0667-2. PMID: 32268347.
- Larsen C, Shahinas J. Dosage, Efficacy and Safety of Cannabidiol Administration in
- Adults: A Systematic Review of Human Trials. J Clin Med Res. 2020;12(3):129-41. Epub
- 613 2020/04/02. doi: 10.14740/jocmr4090. PMID: 32231748.
- Reuveni N, Carlson CA, Schwartz S, Meter D, Barrett TS, Freeman SM. The
- antidepressant and anxiolytic effects of cannabinoids in chronic unpredictable stress: a
- preclinical systematic review and meta-analysis. Transl Psychiatry. 2022;12(1):217. Epub
- 617 2022/06/01. doi: 10.1038/s41398-022-01967-1. PMID: 35641487.
- 618 36. Graczyk M, Lewandowska AA, Dzierżanowski T. The Therapeutic Potential of
- Cannabis in Counteracting Oxidative Stress and Inflammation. Molecules. 2021;26(15). doi:
- 620 10.3390/molecules26154551. PMID: 34361704.
- 621 37. Soliman N, Haroutounian S, Hohmann AG, Krane E, Liao J, Macleod M, et al.
- 622 Systematic review and meta-analysis of cannabinoids, cannabis-based medicines, and
- endocannabinoid system modulators tested for antinociceptive effects in animal models of
- 624 injury-related or pathological persistent pain. Pain. 2021;162(Suppl 1):S26-s44. doi:
- 625 10.1097/j.pain.000000000002269. PMID: 33729209.
- 626 38. Zavala-Tecuapetla C, Luna-Munguia H, López-Meraz ML, Cuellar-Herrera M.
- Advances and Challenges of Cannabidiol as an Anti-Seizure Strategy: Preclinical Evidence.
- 628 Int J Mol Sci. 2022;23(24). doi: 10.3390/ijms232416181. PMID: 36555823.

- 629 39. Esposito G, Pesce M, Seguella L, Sanseverino W, Lu J, Corpetti C, et al. The
- potential of cannabidiol in the COVID-19 pandemic. Br J Pharmacol. 2020;177(21):4967-70.
- 631 doi: 10.1111/bph.15157. PMID: 32519753.
- 632 40. Tadijan A, Vlašić I, Vlainić J, Đikić D, Oršolić N, Jazvinšćak Jembrek M.
- 633 Intracellular Molecular Targets and Signaling Pathways Involved in Antioxidative and
- Neuroprotective Effects of Cannabinoids in Neurodegenerative Conditions. Antioxidants
- 635 [Internet]. 2022; 11(10).
- 636 41. Stohs SJ, Ray SD. Is cannabidiol hepatotoxic or hepatoprotective: A review. Toxicol
- 637 Res Appl. 2020;4:2397847320922944. doi: 10.1177/2397847320922944.
- 638 42. Russo EB. The Case for the Entourage Effect and Conventional Breeding of Clinical
- 639 Cannabis: No "Strain," No Gain. Front Plant Sci. 2018;9:1969. doi: 10.3389/fpls.2018.01969.
- 640 PMID: 30687364.
- 641 43. Russo EB, McPartland JM. Cannabis is more than simply delta(9)-
- tetrahydrocannabinol. Psychopharmacology (Berl). 2003;165(4):431-2; author reply 3-4. doi:
- 643 10.1007/s00213-002-1348-z. PMID: 12491031.
- 644 44. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, et al. An entourage
- effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol
- cannabinoid activity. Eur J Pharmacol. 1998;353(1):23-31. doi: 10.1016/s0014-
- 647 2999(98)00392-6. PMID: 9721036.
- 648 45. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT.
- Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the
- efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with

- intractable cancer-related pain. J Pain Symptom Manage. 2010;39(2):167-79. Epub
- 652 2009/11/10. doi: 10.1016/j.jpainsymman.2009.06.008. PMID: 19896326.
- 653 46. Pamplona FA, da Silva LR, Coan AC. Potential Clinical Benefits of CBD-Rich
- 654 Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data
- 655 Meta-analysis. Front Neurol. 2018;9:759. Epub 2018/09/28. doi: 10.3389/fneur.2018.00759.
- 656 PMID: 30258398.
- 657 47. Shalev N, Kendall M, Anil SM, Tiwari S, Peeri H, Kumar N, et al. Phytocannabinoid
- 658 Compositions from Cannabis Act Synergistically with PARP1 Inhibitor against Ovarian
- Cancer Cells In Vitro and Affect the Wnt Signaling Pathway. Molecules. 2022;27(21). Epub
- 2022/11/12. doi: 10.3390/molecules27217523. PMID: 36364346.
- 48. Anis O, Vinayaka AC, Shalev N, Namdar D, Nadarajan S, Anil SM, et al. Cannabis-
- Derived Compounds Cannabichromene and Δ9-Tetrahydrocannabinol Interact and Exhibit
- 663 Cytotoxic Activity against Urothelial Cell Carcinoma Correlated with Inhibition of Cell
- Migration and Cytoskeleton Organization. Molecules. 2021;26(2). Epub 2021/01/23. doi:
- 665 10.3390/molecules26020465. PMID: 33477303.
- 666 49. Blasco-Benito S, Seijo-Vila M, Caro-Villalobos M, Tundidor I, Andradas C, García-
- Taboada E, et al. Appraising the "entourage effect": Antitumor action of a pure cannabinoid
- versus a botanical drug preparation in preclinical models of breast cancer. Biochem
- Pharmacol. 2018;157:285-93. Epub 2018/06/26. doi: 10.1016/j.bcp.2018.06.025. PMID:
- 670 29940172.
- 671 50. Bonn-Miller MO, ElSohly MA, Loflin MJE, Chandra S, Vandrey R. Cannabis and
- cannabinoid drug development: evaluating botanical versus single molecule approaches. Int

- Rev Psychiatry. 2018;30(3):277-84. doi: 10.1080/09540261.2018.1474730. PMID:
- 674 30179534.
- 675 51. Rice LJ, Cannon L, Dadlani N, Cheung MMY, Einfeld SL, Efron D, et al. Efficacy of
- cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and
- adolescents: a systematic review. European Child & Adolescent Psychiatry. 2023:1-22.
- 678 52. Aran A, Cassuto H, Lubotzky A, Wattad N, Hazan E. Brief report: cannabidiol-rich
- cannabis in children with autism spectrum disorder and severe behavioral problems—a
- retrospective feasibility study. Journal of Autism and Developmental Disorders.
- 681 2019;49(3):1284-8.
- 682 53. Barchel D, Stolar O, De-Haan T, Ziv-Baran T, Saban N, Fuchs DO, et al. Oral
- 683 Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms
- and Co-morbidities. Front Pharmacol. 2019;9:1521. doi: 10.3389/fphar.2018.01521. PMID:
- 685 30687090.
- 686 54. Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V. Real life
- experience of medical cannabis treatment in autism: analysis of safety and efficacy. Scientific
- 688 reports. 2019;9(1):1-7.
- 689 55. Fleury-Teixeira P, Caixeta FV, Ramires da Silva LC, Brasil-Neto JP, Malcher-Lopes
- R. Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder
- 691 Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use.
- 692 Front Neurol. 2019;10:1145. Epub 2019/11/19. doi: 10.3389/fneur.2019.01145. PMID:
- 693 31736860.

- 694 56. Bilge S, Ekici B. CBD-enriched cannabis for autism spectrum disorder: an experience
- of a single center in Turkey and reviews of the literature. J Cannabis Res. 2021;3(1):53. Epub
- 696 2021/12/17. doi: 10.1186/s42238-021-00108-7. PMID: 34911567.
- 697 57. Hacohen M, Stolar OE, Berkovitch M, Elkana O, Kohn E, Hazan A, et al. Children
- and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements
- particularly in social symptoms: an open label study. Translational Psychiatry.
- 700 2022;12(1):375.
- 701 58. Aran A, Harel M, Cassuto H, Polyansky L, Schnapp A, Wattad N, et al. Cannabinoid
- treatment for autism: a proof-of-concept randomized trial. Molecular autism. 2021;12(1):1-
- 703 11.
- da Silva Junior EA, Medeiros WMB, Dos Santos JPM, de Sousa JMM, da Costa FB,
- Pontes KM, et al. Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in
- children with autism spectrum disorder: randomized, double-blind and controlled placebo
- clinical trial. Trends in Psychiatry and Psychotherapy. 2022; (AheadOfPrint):0-.
- 708 60. Schnapp A, Harel M, Cayam-Rand D, Cassuto H, Polyansky L, Aran A. A Placebo-
- 709 Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and
- Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by
- 711 the CSHQ. Biomedicines. 2022;10(7):1685.
- 712 61. Lord C, Rutter M, DiLavore P, Risi S, Gotham K, Bishop S, et al. Autism Diagnostic
- Observation Schedule: ADOS-2| Pearson Assessment. Pearson.; 2012.
- Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, et al. Efficacy
- and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis. Drugs.


- 716 2018;78(17):1791-804. Epub 2018/11/06. doi: 10.1007/s40265-018-0992-5. PMID:
- 717 30390221.
- 718 63. Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, et al. Evidence for
- cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational
- evidence. J Neurol Neurosurg Psychiatry. 2018;89(7):741-53. Epub 2018/03/08. doi:
- 721 10.1136/jnnp-2017-317168. PMID: 29511052.
- 722 64. Devinsky O, Cross JH, Wright S. Trial of Cannabidiol for Drug-Resistant Seizures in
- the Dravet Syndrome. N Engl J Med. 2017;377(7):699-700. doi: 10.1056/NEJMc1708349.
- 724 PMID: 28813226.
- 725 65. Busner J, Targum SD. The clinical global impressions scale: applying a research tool
- 726 in clinical practice. Psychiatry (Edgmont). 2007;4(7):28-37. PMID: 20526405.
- 727 66. Rodgers J, Wigham S, McConachie H, Freeston M, Honey E, Parr JR. Development
- of the anxiety scale for children with autism spectrum disorder (ASC-ASD). Autism Res.
- 729 2016;9(11):1205-15.
- 730 67. Bruni O, Ottaviano S, Guidetti V, Romoli M, Innocenzi M, Cortesi F, et al. The Sleep
- 731 Disturbance Scale for Children (SDSC). Construction and validation of an instrument to
- evaluate sleep disturbances in childhood and adolescence. J Sleep Res. 1996;5(4):251-61.
- 733 doi: 10.1111/j.1365-2869.1996.00251.x. PMID: 9065877.
- 68. Efron D, Freeman JL, Cranswick N, Payne JM, Mulraney M, Prakash C, et al. A pilot
- randomised placebo-controlled trial of cannabidiol to reduce severe behavioural problems in
- children and adolescents with intellectual disability. British Journal of Clinical
- 737 Pharmacology. 2021;87(2):436-46.

- 738 69. Chen H, Yang T, Chen J, Chen L, Dai Y, Zhang J, et al. Sleep problems in children
- with autism spectrum disorder: a multicenter survey. BMC Psychiatry. 2021;21(1):406. Epub
- 740 2021/08/18. doi: 10.1186/s12888-021-03405-w. PMID: 34399715.
- 741 70. Malow BA, Katz T, Reynolds AM, Shui A, Carno M, Connolly HV, et al. Sleep
- Difficulties and Medications in Children With Autism Spectrum Disorders: A Registry Study.
- Pediatrics. 2016;137 Suppl 2:S98-s104. Epub 2016/02/26. doi: 10.1542/peds.2015-2851H.
- 744 PMID: 26908483.
- 745 71. Stolar O, Hazan A, Vissoker RE, Kishk IA, Barchel D, Lezinger M, et al. Medical
- cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder:
- An interim analysis of biochemical safety. Front Pharmacol. 2022;13:977484. Epub
- 748 2022/10/18. doi: 10.3389/fphar.2022.977484. PMID: 36249785.
- 749 72. Silva EADJ, Medeiros WMB, Torro N, Sousa JMM, Almeida I, Costa FBD, et al.
- 750 Cannabis and cannabinoid use in autism spectrum disorder: a systematic review. Trends
- 751 Psychiatry Psychother. 2022;44:e20200149. Epub 2021/05/28. doi: 10.47626/2237-6089-
- 752 2020-0149. PMID: 34043900.
- 753 73. Kalvin CB, Marsh CL, Ibrahim K, Gladstone TR, Woodward D, Grantz H, et al.
- Discrepancies between parent and child ratings of anxiety in children with autism spectrum
- disorder. Autism Res. 2020;13(1):93-103. Epub 2019/10/24. doi: 10.1002/aur.2220. PMID:
- 756 31643143.

758 Figure Legend

759 Fig 1. Clinical Global Impression – Global Improvement.

- **Fig 2. Clinical Global Impression Severity of Illness.**
- Fig 3. Clinical Global Impression Therapeutic Effect after 28 days of treatment.



Figure

GLOBAL IMPROVEMENT RATINGS


1. Very much improved

2. Much improved

3. Minimally improved

4. No change

Figure



Therapeutic Effect

EFFICACY INDEX SCORES

2 = Marked Therapeutic Effect, Vast improvement. Complete or nearly complete remission of all symptoms.

Side Effects: Do not significantly interfere with patient's functioning.

5 = Moderate Therapeutic Effect, Decided improvement. Partial remission of symptoms.

Side Effects: None.

6 = Moderate Therapeutic Effect, Decided improvement. Partial remission of symptoms.

Side Effects: Do not significantly interfere with patient's functioning.

9 = Minimal Therapeutic Effect, Slight improvement which doesn't alter status of care of patient.

Side Effects: None.

13 = Unchanged or worse.

Side effects: None.